ABSI · Absci Corp
$9.18
-0.28 (-2.96%)
At close · Aug 14
Market Cap
$1.58B
Shares
171.61M
Absci Corp Earnings Call Transcripts
Every quarterly earnings call for Absci Corp (ABSI) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲53.9%
$2.37M
−$27.26M
'22 Q3
22-11-09
▲7.2%
$1.56M
−$19.47M
'22 Q4
23-03-30
▲54.9%
$1.27M
−$23.36M
'23 Q1
23-05-15
▲236%
$3.37M
−$41.67M
'23 Q2
23-08-14
▼68.6%
$744,000
−$21.99M
'23 Q3
23-11-14
▼78.3%
$338,000
−$23.55M
'23 Q4
24-03-21
▼29.2%
$898,000
−$21.98M
'24 Q1
24-05-14
▼62.3%
$1.27M
−$24.75M
'24 Q2
24-08-14
▲128.6%
$1.70M
−$27.40M
'24 Q3
24-11-12
▲96.7%
$665,000
−$28.98M
'24 Q4
25-03-18
▲31.3%
$1.18M
−$26.35M
'25 Q1
25-05-13
▼53.3%
$593,000
−$30.57M
'25 Q2
25-08-12
▼77.8%
$378,000
−$28.71M
'25 Q3
25-12-11
▼2.3%
$650,000
−$29.56M
'25 Q4
26-03-24
▼81.8%
$215,000
−$29.60M
'26 Q1
26-05-07
LATEST
▼46.4%
$318,000
−$33.21M
'26 Q2
26-08-11
Earnings call
FY26 · Q2
2026-08-11
Absci Second Quarter 2026 Business Update and Financial and Operating Results Conference Call
Revenue
$318,000
▼ 46.4% YoY Diluted EPS
$-0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
2026 Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Absci Corp Q1 FY2026 Earnings Call
Confident tone
ABS-201 androgenic alopecia (AGA) program
Pipeline expansion - prolactin / ABS-202
Endometriosis indication
Revenue
$215,000
▼ 81.8% YoY Diluted EPS
$-0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
Absci Corp Q4 FY2025 Earnings Call
Confident tone
ABS-201 clinical progress
Androgenetic alopecia (AGA) opportunity
R&D efficiency
Revenue
$650,000*
▼ 2.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-12-11
Absci Corp Q3 FY2025 Earnings Call
Confident tone
ABS-101 phase one interim results and partnership decision
Pipeline reprioritization and capital discipline
ABS-301 immuno-oncology and other partnered programs
Revenue
$378,000
▼ 77.8% YoY Diluted EPS
$-0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Absci Corp Q2 FY2025 Earnings Call
Confident tone
ABS-101 anti-TL1A clinical progress
ABS-201 androgenetic alopecia program
Almirall collaboration expansion
Revenue
$593,000
▼ 53.3% YoY Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Absci Corp Q1 FY2025 Earnings Call
Confident tone
ABS-101 TL1A Clinical Milestone
ABS-201 Androgenic Alopecia Program
Business Development and Partnerships
Revenue
$1.18M
▲ 31.3% YoY Diluted EPS
$-0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-18
Absci Corp Q4 FY2024 Earnings Call
Confident tone
ABS-101 anti-TL1A program
ABS-201 anti-prolactin receptor / androgenic alopecia
Pipeline and partner ecosystem growth
Revenue
$665,000*
▲ 96.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Absci Corp Q3 FY2024 Earnings Call
Confident tone
ABS-201 Dermatology Program
ABS-101 TL1A Program
R&D Day Catalyst
Revenue
$1.70M
▲ 128.6% YoY Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Absci Corp Q2 FY2024 Earnings Call
Confident tone
New MSK Partnership
ABS-101 Anti-TL1A Program
Partnership Pipeline / Business Development
Revenue
$1.27M
▼ 62.3% YoY Diluted EPS
$-0.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Absci Corp Q1 FY2024 Earnings Call
Confident tone
Platform efficiency and cost advantage
Internal pipeline progress
Partnerships and business development
Revenue
$898,000
▼ 29.2% YoY Diluted EPS
$-0.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-21
Absci Corp Q4 FY2023 Earnings Call
Revenue
$338,000*
▼ 78.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Absci Corp Q3 FY2023 Earnings Call
Revenue
$744,000
▼ 68.6% YoY Diluted EPS
$-0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Absci Corp Q2 FY2023 Earnings Call
Revenue
$3.37M
▲ 236% YoY Diluted EPS
$-0.45
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
Absci Corp Q1 FY2023 Earnings Call
Revenue
$1.27M
▲ 54.9% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-30
Absci Corp Q4 FY2022 Earnings Call
Revenue
$1.56M*
▲ 7.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Absci Corp Q3 FY2022 Earnings Call
Revenue
$2.37M
▲ 53.9% YoY Diluted EPS
$-0.30
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Absci Corp Q2 FY2022 Earnings Call
Revenue
$1.00M
▲ 37.6% YoY Diluted EPS
$-0.32
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Absci Corp Q1 FY2022 Earnings Call
Revenue
$819,000
▼ 23% YoY Diluted EPS
$-0.33
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-22
Absci Corp Q4 FY2021 Earnings Call
Revenue
$1.45M*
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Absci Corp Q3 FY2021 Earnings Call
Revenue
$1.54M
▲ 68% YoY Diluted EPS
$-0.33
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Showing 1–22 of 22 earnings calls
Key facts
CIK
1672688
CUSIP
00091E109
13F (30d)
195 filings
193 filers
Visit website
Investor relations